RNA biomarkers shed light on osteoarthritis

In research presented at the Orthopaedic Research Society 2012 annual meeting, two biomarkers have come to light that might help in the development of disease-modifying treatments for osteoarthritis, a painful joint condition that is a result of wear and tear on the cartilage. Researchers at Henry Ford Hospital in Detroit have linked the two biomarkers, short stretches of genetic material known as non-coding RNAs, with mild cartilage damage. Gary Gibson, director of Henry Ford's Bone and Joint Center and the study's lead author, said the results might suggest the discovery of a long-awaited biomarker for osteoarthritis, a leading cause of disability. The next step is to find out whether the concentration of the biomarkers can be linked with worsening cartilage damage. Press release

Suggested Articles

Medtronic has moved to acquire Avenu Medical, developers of a minimally invasive method of building the blood vessel access ports.

The agency also gave the company’s diagnostic, run on the high-throughput Panther Fusion laboratory platform, a green light for pooled testing.

Smith & Nephew has signed up to acquire Integra LifeSciences’ orthopedics business focused on the growing upper and lower extremity markets.